Resveratrol as a phytoestrogen

Resveratrol in Health and Disease

Volumn , Issue , 2005, Pages 439-464

  Gehm, Barry D ^a   Levenson, Anait S ^b  

^a LYON COLLEGE   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84887834109     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/9781420026474     Document Type: Chapter

References (81)

1. Bradbury RB and White DE, Oestrogens and related substances in plants, Vitam Horm 12, 207-233, 1954.
2. Wynne-Edwards KE, Evolutionary biology of plant defenses against herbivory and their predictive implications for endocrine disruptor susceptibility in vertebrates, Environ Health Perspect 109, 443-448, 2001.
3. Gehm BD, McAndrews JM, Chien P-Y, and Jameson JL, Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor, Proc Natl Acad Sci USA 94, 14138-14143, 1997.
4. Lu R and Serrero G, Resveratrol, a natural product derived from grape, exhibits antiestrogenic activity and inhibits the growth of human breast cancer cells, J Cell Physiol 179, 297-304, 1999.
5. Bowers JL, Tyulmenkov VV, Jernigan SC, and Klinge CM, Resveratrol acts as a mixed agonist/antagonist for estrogen receptors alpha and beta, Endocrinology 141, 3657-3667, 2000.
6. Henry LA and Witt DM, Resveratrol: phytoestrogen effects on reproductive physiology and behavior in female rats, Horm Behav 41, 220-228, 2002.
7. Klinge CM, Risinger KE, Watts MB, Beck V, Eder R, and Jungbauer A, Estrogenic activity in white and red wine extracts, J Agric Food Chem 51, 1850-1857, 2003.
8. Ramsey TL, Risinger KE, Jernigan SC, Mattingly KA, and Klinge CM, Estrogen receptor beta isoforms exhibit differences in ligand-activated transcriptional activity in an estrogen response element sequence-dependent manner, Endocrinology 145, 149-160, 2004.
9. Goldberg DM, Hahn SE, and Parkes JG, Beyond alcohol: beverage consumption and cardiovascular mortality, Clin Chim Acta 237, 155-187, 1995.
10. Orgogozo JM, Dartigues JF, Lafont S, Letenneur L, Commenges D, Salamon R, Renaud S, and Breteler MB, Wine consumption and dementia in the elderly:a prospective community study in the Bordeaux area, Rev Neurol; 153, 185-192, 1997.
11. Lê MG, Hill C, Kramar A, and Flamanti R, Alcoholic beverage consumption and breast cancer in a French case-control study, Am J Epidemiol 120, 350-357, 1984.
12. Viel JF, Perarnau JM, Challier B, and Faivre-Nappez I, Alcoholic calories, red wine consumption and breast cancer among premenopausal women, J Epidemiol 13, 639-643, 1997.
13. Kopp P, Resveratrol, a phytoestrogen found in red wine. A possible explanation of the conundrum of the “French paradox’'? Eur J Endocrinol 138, 619-620, 1998.
14. Nilsson S, Makela S, Treuter E, Tujague M, Thomsen J, Andersson G, Enmark E, Pettersson K, Warner M, and Gustafsson J-A, Mechanisms of estrogen action, Physiol Rev 81, 1535-1565, 2001.
15. Kuiper GGJM, Carlsson B, Grandien K, Enmark E, Häggblad J, Nilsson S, and Gustafsson J-Å, Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta, Endocrinology 138, 863-870, 1997.
16. Adlercreutz CH, Goldin BR, Gorbach SL, Hockerstedt KA, Watanabe S, Hamalainen EK, Markkanen MH, Makela TH, Wahala KT, and Adlercreutz T, Soybean phytoestrogen intake and cancer risk, J Nutr 125, 757S-770S, 1995.
17. Bhat KP and Pezzuto JM, Resveratrol exhibits cytostatic and antiestrogenic properties with human endometrial adenocarcinoma (Ishikawa) cells, Cancer Res 61, 6137-6144, 2001.
18. An J, Tzagarakis-Foster C, Scharschmidt TC, Lomri N, and Leitman DC, Estrogen receptor beta-selective transcriptional activity and recruitment of coregulators by phytoestrogens, J Biol Chem 276, 17808-17814, 2001.
19. Mueller SO, Simon S, Chae K, Metzler M, and Korach KS, Phytoestrogens and their human metabolites show distinct agonistic and antagonistic properties on estrogen receptor alpha (ERa) and ERb in human cells, Toxicol Sci 80, 14-25, 2004.
20. Gehm BD, Levenson AS, Liu H, Lee E-J, Amundsen BM, Cushman M, Jordan VC, and Jameson JL, Estrogenic effects of resveratrol in breast cancer cells expressing mutant and wild-type estrogen receptors: role of AF-1 and AF-2, J Steroid Biochem Mol Biol 88, 223-234, 2004.
21. Levenson AS, Gehm BD, Timm Pearce S, Horiguchi J, Simons LA, Ward JE III, Jameson JL, and Jordan VC, Resveratrol acts as an estrogen receptor (ER) agonist in breast cancer cells stably transfected with ER alpha, Int J Cancer 104, 587-596, 2003.
22. Wietzke JA and Welsh J, Phytoestrogen regulation of a vitamin D3 receptor promoter and 1,25-dihydroxyvitamin D3 actions in human breast cancer cells, J Steroid Biochem Mol Biol 84, 149-157, 2003.
23. Bhat KP, Lantvit D, Christov K, Mehta RG, Moon RC, and Pezzuto JM, Estrogenic and antiestrogenic properties of resveratrol in mammary tumor models, Cancer Res 61, 7456-7463, 2001.
24. Pervaiz S, Resveratrol: from grapevines to mammalian biology, FASEB J 17, 1975-1985, 2003.
25. Basly JP, Marre-Fournier F, Le Bail JC, Habrioux G, and Chulia AJ, Estrogenic/antiestrogenic and scavenging properties of (E)- and (Z)-resveratrol, Life Sci 66, 769-777, 2000.
26. Sun Z, Lu QJ, Wen LQ, Guo SM, Chen YY, and Liu WJ, Establishment and its application of a reporter-based screening model for discovering new ligands of estrogen receptor alpha subtypes [in Chinese], Yao Xue Xue Bao [Acta Pharm Sin] 35, 747-751, 2000.
27. Ashby J, Tinwell H, Pennie W, Brooks AN, Lefevre PA, Beresford N, and Sumpter JP, Partial and weak oestrogenicity of the red wine constituent resveratrol: consideration of its superagonist activity in MCF-7 cells and its suggested cardiovascular protective effects, J Appl Toxicol 19, 39-45, 1999.
28. Serrero G and Lu R, Effect of resveratrol on the expression of autocrine growth modulators in human breast cancer cells, Antioxid Redox Signal 3, 969-979, 2001.
29. Yoon K, Pellaroni L, Ramamoorthy K, Gaido K, and Safe S, Ligand structuredependent differences in activation of estrogen receptor alpha in human HepG2 liver and U2 osteogenic cancer cell lines, Mol Cell Endocrinol 162, 211-220, 2000.
30. Yoon K, Pallaroni L, Stoner M, Gaido K, and Safe S, Differential activation of wild-type and variant forms of estrogen receptor alpha by synthetic and natural estrogenic compounds using a promoter containing three estrogen-responsive elements, J Steroid Biochem Mol Biol 78, 25-32, 2001.
31. Safe SH, Pallaroni L, Yoon K, Gaido K, Ross S, and McDonnell D, Problems for risk assessment of endocrine-active estrogenic compounds, Environ Health Perspect 110 (Suppl 6), 925-929, 2002.
32. El-Mowafy AM, Abou-Zeid LA, and Edafiogho I, Recognition of resveratrol by the human estrogen receptor-alpha: a molecular modeling approach to understand its biological actions, Med Princ Pract 11, 86-92, 2002.
33. Levenson AS and Jordan VC, Selective oestrogen receptor modulation:molecular pharmacology for the millennium, Eur J Cancer 35, 1974-1985, 1999.
34. Levenson AS and Jordan VC, The key to the antiestrogenic mechanism of raloxifene is amino acid 351 (aspartate) in the estrogen receptor, Cancer Res 58, 1872-1875, 1998.
35. Levenson AS, MacGregor Schafer JI, Bentrem DJ, Pease KM, and Jordan VC, Control of the estrogen-like actions of the tamoxifen-estrogen receptor complex by the surface amino acid at position 351, J Steroid Biochem Mol Biol 76, 61-70, 2001.
36. Jordan VC, Schafer JM, Levenson AS, Liu H, Pease KM, Simons LA, and Zapf JW, Molecular classification of estrogens, Cancer Res 61, 6619-6623, 2001.
37. Mizutani K, Ikeda K, Kawai Y, and Yamori Y, Resveratrol stimulates the proliferation and differentiation of osteoblastic MC3T3-E1 cells, Biochem Biophys Res Commun 253, 859-863, 1998.
38. Stahl S, Chun TY, and Gray WG, Phytoestrogens act as estrogen agonists in an estrogen-responsive pituitary cell line, Toxicol Appl Pharmacol 152, 41-48, 1998.
39. Pozo-Guisado E, Lorenzo-Benayas MJ, and Fernandez-Salguero PM, Resveratrol modulates the phosphoinositide 3-kinase pathway through an estrogen receptor alpha-dependent mechanism: relevance in cell proliferation, Int J Cancer 109, 167-173, 2004.
40. Brownson DM, Azios NG, Fuqua BK, Dharmawardhane SF, and Mabry TJ, Flavonoid effects relevant to cancer, J Nutr 132, 3482S-3489S, 2002.
41. Levenson AS, Kliakhandler IL, Svoboda KM, Pease KM, Kaiser SA, Ward JE III, and Jordan VC, Molecular classification of selective oestrogen receptor modulators on the basis of gene expression profiles of breast cancer cells expressing oestrogen receptor alpha, Br J Cancer 87, 449-456, 2002.
42. Levenson AS, Svoboda KM, Pease KM, Kaiser SA, Chen B, Simons LA, Jovanovic BD, Dyck PA, and Jordan VC, Gene expression profiles with activation of the estrogen receptor a-selective estrogen receptor modulator complex in breast cancer cells expressing wild-type estrogen receptor, Cancer Res 62, 4419-4426, 2002.
43. Ahmad N, Adhami VM, Afaq F, Feyes DK, and Mukhtar H, Resveratrol causes WAF-1/p21-mediated G(1)-phase arrest of cell cycle and induction of apoptosis in human epidermoid carcinoma A431 cells, Clin Cancer Res 7, 1466-1473, 2001.
44. Mitchell SH, Zhu W, and Young CY, Resveratrol inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells, Cancer Res 59, 5892-5895, 1999.
45. Tessitore L, Davit A, Sarotto I, and Caderni G, Resveratrol depresses the growth of colorectal aberrant crypt foci by affecting bax and p21(CIP) expression, Carcinogenesis 21, 1619-1622, 2000.
46. Nuttall ME, Bradbeer JN, Stroup GB, Nadeau DP, Hoffman SJ, Zhao H, Rehm S, and Gowen M, Idoxifene: a novel selective estrogen receptor modulator prevents bone loss and lowers cholesterol levels in ovariectomized rats and decreases uterine weight in intact rats, Endocrinology 139, 5224-5234, 1998.
47. Chander SK, McCague R, Luqmani Y, Newton C, Dowsett M, Jarman M, and Coombes RC, Pyrrolidino-4-iodotamoxifen and 4-iodotamoxifen, new analogues of the antiestrogen tamoxifen for the treatment of breast cancer, Cancer Res 51, 5851-5858, 1991.
48. Jiang SY and Jordan VC, Growth regulation of estrogen receptor-negative breast cancer cells transfected with complementary DNAs for estrogen receptor, J Natl Cancer Inst 84, 580-591, 1992.
49. Levenson AS and Jordan VC, Transfection of human estrogen receptor (ER) cDNA into ER-negative mammalian cell lines, J Steroid Biochem Mol Biol 51, 229-239, 1994.
50. Schmitt E, Lehmann L, Metzler M, and Stopper H, Hormonal and genotoxic activity of resveratrol, Toxicol Lett 136, 133-142, 2002.
51. Mgbonyebi OP, Russo J, and Russo IH, Antiproliferative effect of synthetic resveratrol on human breast epithelial cells, Int J Oncol 12, 865-869, 1998.
52. Hsieh TC, Burfeind P, Laud K, Backer JM, Traganos F, Darzynkiewicz Z, and Wu JM, Cell cycle effects and control of gene expression by resveratrol in human breast carcinoma cell lines with different metastatic potentials, Int J Oncol 15, 245-252, 1999.
53. Nakagawa H, Kiyozuka Y, Uemura Y, Senzaki H, Shikata N, Hioki K, and Tsubura A, Resveratrol inhibits human breast cancer cell growth and may mitigate the effect of linoleic acid, a potent breast cancer cell stimulator, J Cancer Res Clin Oncol 127, 258-264, 2001.
54. Damianaki A, Bakogeorgou E, Kampa M, Notas G, Hatzoglou A, Panagiotou S, Gemetzi C, Kouroumalis E, Martin PM, and Castanas E, Potent inhibitory action of red wine polyphenols on human breast cancer cells, J Cell Biochem 78, 429-441, 2000.
55. Goldberg DM, Yan J, Ng E, Diamandis EP, Karumanchiri A, Soleas G, and Waterhouse AL, A global survey of trans-resveratrol concentrations in commercial wines, Am J Enol Vitic 46, 159-165, 1995.
56. Slater I, Odum J, and Ashby J, Resveratrol and red wine consumption, Hum Exp Toxicol 18, 625-626, 1999.
57. Turner RT, Evans GL, Zhang M, Maran A, and Sibonga JD, Is resveratrol an estrogen agonist in growing rats? Endocrinology 140, 50-54, 1999.
58. Freyberger A, Hildebrand H, and Krötlinger F, Differential response of immature rat uterine tissue to ethinylestradiol and the red wine constituent resveratrol, Arch Toxicol 74, 709-715, 2001.
59. Mizutani K, Ikeda K, Kawai Y, and Yamori Y, Resveratrol attenuates ovariectomy-induced hypertension and bone loss in stroke-prone spontaneously hypertensive rats, J Nutr Sci Vitaminol (Tokyo) 46, 78-83, 2000.
60. Kubo K, Arai O, Omura M, Watanabe R, Ogata R, and Aou S, Low dose effects of bisphenol A on sexual differentiation of the brain and behavior in rats, Neurosci Res 45, 345-356, 2003.
61. Liu Z, Yu B, Li W, Sun J, Huang J, Huo J, and Liu C, Estrogenicity of trans-resveratrol in immature mice in vivo [in Chinese], Wei Sheng Yan Jiu [J Hygiene Res] 31, 188-190, 2002.
62. Ratna WN and Simonelli JA, The action of dietary phytochemicals quercetin, catechin, resveratrol and naringenin on estrogen-mediated gene expression, Life Sci 70, 1577-1589, 2002.
63. Adlercreutz H, Mazur W, Heinonen S-M, and Stumpf K, Phytoestrogens and breast cancer, in Breast Cancer: Prognosis, Treatment, and Prevention, Pasqualini JR, Ed, Marcel Dekker, New York, 2002, pp. 527-554.
64. Bianchini F and Vainio H, Wine and resveratrol: mechanisms of cancer prevention? Eur J Cancer Prev 12, 417-425, 2003.
65. Zhang Y, Kreger BE, Dorgan JF, Splansky GL, Cupples LA, and Ellison RC, Alcohol consumption and risk of breast cancer: the Framingham Study revisited, Am J Epidemiol 149, 93-101, 1999.
66. Smith-Warner SA, Spiegelman D, Yaun SS, van den Brandt PA, Folsom AR, Goldbohm RA, Graham S, Holmberg L, Howe GR, Marshall JR, Miller AB, Potter JD, Speizer FE, Willett WC, Wolk A, and Hunter DJ, Alcohol and breast cancer in women: a pooled analysis of cohort studies, JAMA 279, 535-540, 1998.
67. Freudenheim JL, Marshall JR, Graham S, Laughlin R, Vena JE, Swanson M, Ambrosone C, and Nemoto T, Lifetime alcohol consumption and risk of breast cancer, Nutr Cancer 23, 1-11, 1995.
68. Martin-Moreno JM, Boyle P, Gorgojo L, Willett WC, Gonzalez J, Villar F, and Maisonneuve P, Alcoholic beverage consumption and risk of breast cancer in Spain, Cancer Causes Control 4, 345-353, 1993.
69. Jain MG, Ferrenc RG, Rehm JT, Bondy SJ, Rohan TE, Ashley MJ, Cohe JE, and Miller AB, Alcohol and breast cancer mortality in a cohort study, Breast Cancer Res Treat 64, 201-209, 2000.
70. Bertelli AA, Giovannini L, Stradi R, Bertelli A, and Tillement JP, Plasma, urine and tissue levels of trans- and cis-resveratrol (3,40,5-trihydroxystilbene) after short-term or prolonged administration of red wine to rats, Int J Tissue React 18, 67-71, 1996.
71. Goldberg DM, Yan J, and Soleas GJ, Absorption of three wine-related polyphenols in three different matrices by healthy subjects, Clin Biochem 36, 79-87, 2003.
72. Meng X, Maliakal P, Lu H, Lee MJ, and Yang CS, Urinary and plasma levels of resveratrol and quercetin in humans, mice, and rats after ingestion of pure compounds and grape juice, J Agric Food Chem 52, 935-942, 2004.
73. Asensi M, Medina I, Ortega A, Carretero J, Bano MC, Obrador E, and Estrela JM, Inhibition of cancer growth by resveratrol is related to its low bioavailability, Free Radical Biol Med 33, 387-398, 2002.
74. Gescher AJ and Steward WP, Relationship between mechanisms, bioavailibility, and preclinical chemopreventive efficacy of resveratrol: a conundrum, Cancer Epidemiol Biomarkers Prev 12, 953-957, 2003.
75. Banerjee S, Bueso-Ramos C, and Aggarwal BB, Suppression of 7,12- dimethylbenz(a)anthracene-induced mammary carcinogenesis in rats by resveratrol:role of nuclear factor-kappaB, cyclooxygenase 2, and matrix metalloprotease 9, Cancer Res 62, 4945-4954, 2002.
76. Pace-Asciak CR, Hahn S, Diamandis EP, Soleas G, and Goldberg DM, The red wine phenolics trans-resveratrol and quercetin block human platelet aggregation and eicosanoid synthesis: implications for protection against coronary heart disease, Clin Chim Acta 235, 207-219, 1995.
77. Pace-Asciak CR, Rounova O, Hahn SE, Diamandis EP, and Goldberg DM, Wines and grape juices as modulators of platelet aggregation in healthy human subjects, Clin Chim Acta 246, 163-182, 1996.
78. Martinez-Campos A, Amara JF, and Dannies PS, Antiestrogens are partial estrogen agonists for prolactin production in primary pituitary cultures, Mol Cell Endocrinol 48, 127-133, 1986.
79. Horwitz KB, Koseki Y, and McGuire WL, Estrogen control of progesterone receptor in human breast cancer: role of estradiol and antiestrogen, Endocrinology 103, 1742-1751, 1978.
80. Gehm BD, McAndrews JM, Jordan VC, and Jameson JL, EGF activates highly selective estrogen-responsive reporter plasmids by an ER-independent pathway, Mol Cell Endocrinol 159, 53-62, 2000.
81. Tonetti DA, Rubenstein R, DeLeon M, Zhao H, Pappas SG, Bentrem DJ, Chen B, Constantinou A, and Jordan VC, Stable transfection of an estrogen receptor beta cDNA isoform into MDA-MB-231 breast cancer cells, J Steroid Biochem Mol Biol 87, 47-55, 2003.